HNC364 vs Safinamide

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Parkinson's Disease

Shared mechanism: MAO-B · full Parkinson's Disease pipeline

HNC364

Developed by Guangzhou Henovcom Bioscience Co. Ltd.

Phase 1 in Parkinson's Diseasesmall molecule
Weak signal

NCT05523570 · Phase 1 · completed

Participants were not randomized and neither they nor the investigators were blinded, and there was no placebo or comparator group, so this design cannot separate a real drug effect from chance, natural variation, or expectation. Results have not yet been posted.

Next expected readout: December 2026 · NCT06798519 (registry estimate)

No aligned efficacy figure on record for this race.

Safinamide · Xadago

Marketed by Supernus Pharmaceuticals and partners

Approved in Parkinson's Diseasesmall molecule
Partial signal

NCT00605683 · Phase 3 · completed

The study was randomized and double-blind, included 679 participants, and compared two safinamide doses with placebo. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Next expected readout: December 2027 · NCT07761936 (registry estimate)

Reported efficacy

Change From Baseline to Week 16 in the Mean Total Daily "OFF" Time (At baseline and Week 16): Change From Baseline to Week 16 in the Mean Total Daily "OFF" Time (At baseline and Week 16): Safinamide -1.93 Hours (Standard Deviation 2.556) vs Placebo -0.88 Hours (Standard Deviation 2.543) (met)

Result source: NCT03881371

Results for Parkinson's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointHNC364Safinamide
OFF time, change—Not reported-1.9 vs -0.9−1 vs placebowk 16 · n 151NCT03881371
ON time without troublesome dyskinesia, change—Not reported—Not posted · NCT00643045
UPDRS Part III, change—Not reported—Not posted · NCT00643045
MDS-UPDRS Part II, change—Not reported—Not posted · NCT00643045

OFF time, change

HNC364
—Not reported
Safinamide
-1.9 vs -0.9−1 vs placebowk 16 · n 151NCT03881371

ON time without troublesome dyskinesia, change

HNC364
—Not reported
Safinamide
—Not posted · NCT00643045

UPDRS Part III, change

HNC364
—Not reported
Safinamide
—Not posted · NCT00643045

MDS-UPDRS Part II, change

HNC364
—Not reported
Safinamide
—Not posted · NCT00643045
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

HNC364: no structured comparison results are available for Parkinson's Disease.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. HNC364: 0 of 4 rows · Safinamide: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricSafinamide
Dropout rate
10.5%a
NCT03881371 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 2 more results
19.4%100 mg
NCT05312632 · Phase 4 · registry result, not featured evidence · add on
17.4%
NCT03841604 · Phase 4 · registry result, not featured evidence
Discontinued due to AEs
5.2%a
NCT03881371 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 2 more results
6%100 mg
NCT05312632 · Phase 4 · registry result, not featured evidence · add on
8.7%
NCT03841604 · Phase 4 · registry result, not featured evidence
Serious AEs
5.3%a
NCT03881371 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 2 more results
2%100 mg
NCT05312632 · Phase 4 · registry result, not featured evidence · add on
0%
NCT03841604 · Phase 4 · registry result, not featured evidence
Most frequent reported AEs
a
dyskinesia 11.9% (placebo 3.9%)
back pain 6% (placebo 3.9%)
dizziness 6% (placebo 6.5%)
NCT03881371 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 2 more results
100 mg
overdose 6.5%
dyskinesia 5.5%
covid-19 2.5%
NCT05312632 · Phase 4 · registry result, not featured evidence · add on
constipation 6.5% (placebo 0%)
back pain 4.3% (placebo 0%)
dyskinesia 4.3% (placebo 0%)
NCT03841604 · Phase 4 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 2 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Safinamide

OFF Time -1.93 vs -0.88 placebo hours @ 16wk
absolute change · hours
NCT03881371 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
Pain NRS 0 vs 0 placebo score @ 16wk
absolute change · score
NCT03881371 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 2 more results
-1.6 vs -0.8 placebo score @ 16wk
NCT03841604 · Phase 4 · registry result, not featured evidence
-1.6 vs -0.8 placebo score @ 16wk
NCT03841604 · Phase 4 · registry result, not featured evidence
Daily "ON" Time 1.3 vs 0.51 placebo hours @ 16wk
absolute change · hours
NCT03881371 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
On-time No Troublesome Dyskinesia 1.3 vs 0.39 placebo hours @ 16wk
absolute change · hours
NCT03881371 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
UPDRS Total -12.3 vs -5.8 placebo score @ 16wk
absolute change · score
NCT03881371 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
UPDRS Part II ADL -2.7 vs -1.2 placebo score @ 16wk
absolute change · score
NCT03881371 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
UPDRS Part III (Motor -8.2 vs -3.7 placebo score @ 16wk
absolute change · score
NCT03881371 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
CGI-S 3.6 vs 3.8 placebo score @ 16wk
absolute value · score
NCT03881371 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 1 more result
3.4 vs 3.5 placebo score @ 16wk
NCT03841604 · Phase 4 · registry result, not featured evidence
CGI-C 3 vs 3.4 placebo score @ 16wk
absolute value · score
NCT03881371 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 1 more result
3.4 vs 3.5 placebo score @ 16wk
NCT03841604 · Phase 4 · registry result, not featured evidence
PDQ-39 -6.42 vs -2.67 placebo score @ 16wk
absolute change · score
NCT03881371 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
OFF Time -0.8 hours @ 18wk100 mg
absolute change · hours
No placebo or comparator arm
NCT05312632 · Phase 4 · registry result, not featured evidence · add on
PDQ-39 Summary Index -2.7 score @ 18wk100 mg
absolute change · score
No placebo or comparator arm
NCT05312632 · Phase 4 · registry result, not featured evidence · add on

+ 9 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HNC364's landscape · Safinamide's landscape